Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Immutep Limited (IMMP) stock profile

Immutep Limited is a biotechnology company engaged in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003, in a Phase IIb clinical trial for HNSCC; and INSIGHT-004 and INSIGHT-003, in a Phase I clinical trial for solid tumors, as well as INSIGHT-005, in a Phase I/IIa clinical trial for solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that stimulates T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Incorporated in 1987, Immutep is based in Sydney, Australia.

Key facts

SymbolIMMP
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOMarc Voigt
Employees41
HeadquartersSydney, NSW, AU
IPO2012-04-19
Websitewww.immutep.com

Explore IMMP on Vantafin

  • Immutep Limited Overview
  • Immutep Limited Financials
  • Immutep Limited News
  • Immutep Limited Events
  • Immutep Limited SEC filings
  • Immutep Limited Transcripts

Frequently asked questions

What does Immutep Limited (IMMP) do?
Immutep Limited is a biotechnology company engaged in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003, in a Phase IIb clinical trial for HNSCC; and INSIGHT-004 and INSIGHT-003, in a Phase I clinical trial for solid tumors, as well as INSIGHT-005, in a Phase I/IIa clinical trial for solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that stimulates T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Incorporated in 1987, Immutep is based in Sydney, Australia.
Where is IMMP stock listed?
Immutep Limited trades under the ticker IMMP on NASDAQ.
How can I research IMMP's financials and filings?
Vantafin provides Immutep Limited's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the IMMP profile.